Top Page
Mach7 Technologies
(Sydney:M7T)
Mach7 Technologies (M7T) vs. iShares MSCI Australia ETF (EWA)
Mach7 Technologies Business Overview & Revenue Model
Mach7 Technologies Earnings Call Summary
Mach7 Technologies Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.70M | 33.79M | 17.24M | 30.06M | 27.08M | 19.03M |
| Gross Profit | 1.53M | 8.38M | -6.42M | 9.35M | -2.57M | -7.73M |
| EBITDA | -6.48M | -7.06M | -15.09M | 2.09M | 2.80M | -1.83M |
| Net Income | -10.08M | -6.20M | -7.97M | -1.05M | -4.17M | -9.36M |
Balance Sheet | ||||||
| Total Assets | 54.04M | 64.21M | 73.03M | 82.31M | 78.92M | 76.97M |
| Cash, Cash Equivalents and Short-Term Investments | 18.49M | 23.07M | 26.18M | 23.39M | 25.75M | 18.36M |
| Total Debt | 1.75M | 1.12M | 1.27M | 1.20M | 1.33M | 1.08M |
| Total Liabilities | 15.09M | 18.63M | 21.17M | 22.82M | 20.55M | 19.05M |
| Stockholders Equity | 38.95M | 45.58M | 51.86M | 59.48M | 58.38M | 57.91M |
Cash Flow | ||||||
| Free Cash Flow | -576.28K | 112.92K | 3.30M | -2.97M | 5.94M | 1.40M |
| Operating Cash Flow | -310.91K | 868.59K | 3.45M | -2.61M | 6.37M | 1.50M |
| Investing Cash Flow | -1.08M | -1.70M | -391.31K | -361.01K | -438.56K | -42.33M |
| Financing Cash Flow | -2.46M | -2.43M | -32.08K | -68.63K | 547.61K | 11.21M |
Mach7 Technologies Technical Analysis
Mach7 Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$131.61M | 26.51 | 1.89% | ― | 10.06% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$76.38M | -6.28 | -12.35% | ― | 15.99% | 22.05% | |
47 Neutral | AU$18.13M | 3.95 | -17.05% | ― | 28.91% | -1050.00% | |
44 Neutral | AU$45.05M | -5.70 | -13.83% | ― | 3.61% | -17.03% | |
43 Neutral | AU$80.50M | -6.64 | ― | ― | ― | ― |
Mach7 Technologies Corporate Events
Mach7 Technologies Limited has completed an on‑market share buy‑back of its ordinary fully paid shares on the ASX, repurchasing a total of 6,273,000 securities. The program, which was initially notified to the market in January 2025 and has now received a final buy‑back notification as of 4 March 2026, involved total consideration of approximately AUD 2.24 million.
The conclusion of this buy‑back signals the end of a multi‑stage capital management exercise that has reduced the company’s shares on issue and may be marginally accretive to remaining shareholders. By deploying surplus capital to repurchase stock, Mach7 has demonstrated an ongoing focus on shareholder value, though the relatively modest scale of the transaction suggests a measured approach to balance sheet management rather than a transformational shift in its capital structure.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has completed its on-market share buy-back program, which ran from late January 2025 to early March 2026 and was originally authorised for purchases of up to $5 million in fully paid ordinary shares. The company ultimately repurchased 6,273,000 shares for a total consideration of about $2.24 million at an average price of $0.3501, reducing its share count and potentially enhancing earnings per share and capital management flexibility for existing investors.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has notified the market of the lapse of 90,000 options, originally exercisable at $0.98 and due to expire on 31 August 2026, after the specific conditions attached to these rights were not met or became incapable of being satisfied. The cessation of these options slightly reduces the company’s pool of potential future equity dilution and reflects the conditional nature of some components of its incentive or capital management arrangements.
The announcement, lodged as an Appendix 3H with the ASX, confirms that the change in securities took effect on 28 February 2026 and forms part of Mach7’s routine reporting obligations on its issued capital. While the number of options involved is modest relative to a typical listed company’s overall capital base, the update provides transparency for investors monitoring Mach7’s capital structure and the status of performance-based equity instruments.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.33 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has outlined its vision in conjunction with its H1 FY26 results presentation, positioning itself as a provider of a global imaging electronic medical record. By aiming to complete the patient picture with imaging data integrated into EMRs, the company is signaling a strategic focus on interoperability and comprehensive imaging access that could strengthen its role in clinical decision support and enterprise imaging platforms across healthcare systems.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.34 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies reported first-half FY26 revenue of A$13.7 million, down 23% year on year, as fewer one-off capital software licence deals and some customer churn weighed on results despite recurring revenue rising to 85% of total. Operating expenses fell 6% due to lower staff costs and efficiency gains, but adjusted EBITDA slipped to a loss of A$2.3 million, with NPAT also weakening, although the company maintained a solid balance sheet with A$18.5 million in cash and no debt.
New CEO Teri Thomas highlighted a strategic reset over her first six months, including the launch of the Flamingo architecture, the first contract for Flamingo in December 2025, and a rebuilt sales and marketing model to support sustainable, profitable growth. Management is emphasizing disciplined cost control while redirecting resources toward product innovation, a strengthened “Flight Crew” customer engagement model, and an expanded marketing push, positioning Mach7 to capitalise on provider consolidation and growing global adoption of enterprise imaging in the second half and beyond.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.34 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has notified the market of the lapse of 91,666 options with various expiry dates and prices, and 75,000 options expiring on 31 August 2026 at an exercise price of $0.98. The options have ceased because the conditions attached to these securities were not met or became incapable of being satisfied, resulting in a minor reduction in the company’s pool of potential future equity and clarifying its issued capital structure for investors.
The announcement primarily affects conditional rights rather than currently issued shares, meaning there is no immediate dilution impact for existing shareholders. It does, however, provide transparency around the status of incentive or conditional securities and signals that certain performance or other criteria linked to these options have not been achieved within the required timeframe.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.35 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited has notified the market of the cessation of certain options on issue, with a total of 433,334 options (ASX code M7TAJ) lapsing after the conditions attached to these rights were not met or became incapable of being satisfied. The lapses, which occurred in January 2026, result in a modest reduction in potential future dilution for existing shareholders and marginally streamline the company’s capital structure.
The announcement signals that the company is keeping the market updated on changes to its issued capital, a key governance requirement on the ASX and an important data point for investors monitoring potential equity overhang. While the cessation does not involve cash proceeds or new funding, it clarifies the status of contingent equity instruments and may slightly improve per-share metrics relative to a scenario in which all options converted into ordinary shares.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.36 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies will release its H1 FY26 results for the six months to 31 December 2025 on 27 February 2026 and will host an investor webinar the same day, led by CEO Teri Thomas and CFO Dan Lee. The event, which will be recorded and made available via the company’s investor relations site, offers shareholders and analysts a chance to engage directly with management and gain insights into the company’s recent financial and operational performance.
By scheduling a dedicated results briefing with open Q&A, Mach7 is underscoring its focus on transparency and active investor communication as it competes in the global medical imaging software market. The webinar format enables both existing and prospective stakeholders to assess how the company’s enterprise imaging solutions are tracking against market demand and strategic objectives in healthcare technology.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.36 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies reported a positive operating cash flow in the second quarter of FY26 and maintained a strong debt-free balance sheet with A$18.5 million in cash, as it advances a strategic reset aimed at sustainable, profitable growth. Quarterly sales orders reached A$6.8 million, with 82% representing recurring revenue-type sales, and the company secured its first five-year subscription contract for its new Flamingo Architecture product, validating early market demand and supporting its repositioning “from archive to architecture.” Contracted Annual Recurring Revenue fell to A$26.1 million, down A$2.9 million mainly due to the Veterans Health Administration’s decision to discontinue its NextGen PACS program, but the ARR run rate remained stable at A$23.0 million as renewals and expansions offset these reductions. Management highlighted cost reductions from organisational restructuring and IT efficiencies, improved customer delivery and product ratings, and progress toward MDR compliance and CE Mark, positioning Mach7 for scalable growth and deeper penetration into global imaging markets despite the loss of the VHA-related revenue stream.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.41 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has notified the market that a total of 308,333 options (ASX code M7TAJ), which were exercisable at various prices and on various dates, have lapsed after the conditions attached to these rights were not met or became incapable of being satisfied. The cessation of these options, effective on 15 October 2025 and 31 December 2025, reduces the company’s potential future dilution from option exercises and slightly simplifies its capital structure, information that may be relevant for shareholders assessing Mach7’s outstanding securities and potential equity overhang.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.44 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies has confirmed that the U.S. Veterans Health Administration will halt its NextGen PACS program for the National Teleradiology Program, resulting in the termination of the multi‑vendor project in which Mach7 was a subcontractor. The decision means the VHA will retain its incumbent imaging vendor and that neither the already‑implemented Phase 1, covering limited go‑live in mammography and telestroke, nor the planned Phase 2 will proceed, despite Mach7 having met its initial contractual obligations. While management described the outcome as disappointing, they emphasised that the highly complex, bespoke government project demanded substantial resources and that its cancellation does not alter Mach7’s strategic focus on its broader commercial pipeline, where deal velocity and payment terms are more attractive, and on sustaining growth in recurring revenue and profitability.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.54 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies will release its Q2 FY26 results for the quarter ended 31 December 2025 on 30 January 2026 and will follow the announcement with an investor webinar hosted by CEO Teri Thomas and CFO Dan Lee. The session, open to the investment community and later available as a recording on the company’s investor relations site, underscores Mach7’s ongoing engagement with shareholders and market participants ahead of a key quarterly update for the medical imaging software specialist.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.60 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited has notified the ASX that a total of 160,000 options over its shares have lapsed after failing to meet required vesting or performance conditions by their respective expiry dates. The cessation of these conditional rights, which relate to various option series expiring on different dates and at different exercise prices, results in a reduction of potential future dilution for existing shareholders and reflects an adjustment to the company’s issued capital structure, but does not involve any new capital raising or cash outflow.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited announced the cessation of 73,334 securities due to the expiry of options on November 30, 2025. This development reflects the company’s ongoing management of its financial instruments and capital structure, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited announced a change in the director’s interest, with Teri Jo Thomas acquiring 1,989,189 Performance Rights under the company’s Long Term Incentive Plan. This move, approved at the 2025 Annual General Meeting, reflects the company’s commitment to aligning its leadership’s interests with long-term strategic goals, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
Mach7 Technologies Limited announced the issuance of 1,989,189 unquoted performance rights under an employee incentive scheme. This move is part of the company’s strategy to enhance employee engagement and align their interests with the company’s growth objectives, potentially impacting its operational efficiency and market positioning.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.